Cargando…
Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers
Biosimilars present a necessary and timely opportunity for physicians, patients and healthcare systems. If suitably developed clinically, manufactured to the correct standards and used appropriately, they can positively impact on the financial sustainability of healthcare systems. A critical conside...
Autores principales: | Tabernero, Josep, Vyas, Malvika, Giuliani, Rosa, Arnold, Dirk, Cardoso, Fatima, Casali, Paolo G, Cervantes, Andres, Eggermont, Alexander MM, Eniu, Alexandru, Jassem, Jacek, Pentheroudakis, George, Peters, Solange, Rauh, Stefan, Zielinski, Christoph C, Stahel, Rolf A, Voest, Emile, Douillard, Jean-Yves, McGregor, Keith, Ciardiello, Fortunato |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
ESMO Open
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5419210/ https://www.ncbi.nlm.nih.gov/pubmed/28848668 http://dx.doi.org/10.1136/esmoopen-2016-000142 |
Ejemplares similares
-
Knowledge and use of biosimilars in oncology: a survey by the European Society for Medical Oncology
por: Giuliani, Rosa, et al.
Publicado: (2019) -
Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO)
por: Morgan, Gilberto, et al.
Publicado: (2016) -
Preparing for the incoming wave of biosimilars in oncology
por: Wolff-Holz, Elena, et al.
Publicado: (2018) -
Biosimilars in oncology
por: Tabernero, Josep
Publicado: (2018) -
Reply to ‘Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers’
por: Bakalos, Georgios, et al.
Publicado: (2017)